Newman Ferrara LLP Announces Corporate Governance Investigation of Abeona Therapeutics Inc. – ABEO

NEW YORK--()--Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of stockholders of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”).

Abeona, headquartered in Dallas, Texas, is a clinical-stage biopharmaceutical company that develops gene therapy products for rare diseases. Newman Ferrara’s investigation focuses on decisions made by the Board, without shareholder approval, the result of which significantly diminish shareholder value and do not benefit the Company. Considering the Abeona’s poor performance and mounting losses, it is clear that the Board lacks the ability to fairly assess and oversee the Company’s direction and leadership.

Current Abeona stockholders seeking more information on this matter are invited to contact Newman Ferrara attorneys Jeffrey Norton (jnorton@nfllp.com) or Ryan Jerome (rjerome@nfllp.com) to discuss this investigation and their rights.

Newman Ferrara maintains a multifaceted practice based in New York City with attorneys specializing in complex commercial and multi-party litigation, securities fraud and shareholder litigation, consumer protection, civil rights, and real estate. For more information, please visit the firm website at www.nfllp.com.

Contacts

Newman Ferrara LLP
Jeffrey M. Norton, 212-619-5400
jnorton@nfllp.com

Release Summary

Newman Ferrara LLP Announces Corporate Governance Investigation of Abeona Therapeutics Inc. – ABEO

Contacts

Newman Ferrara LLP
Jeffrey M. Norton, 212-619-5400
jnorton@nfllp.com